Zhang, Y., Wagner, A.K. & Guan, X. Newly approved cancer drugs in China — innovation and clinical benefit. Nat Rev Clin Oncol (2023). https://doi.org/10.1038/s41571-023-00728-3 版权信息 本文系AIDD Pro接受的外部投稿,文中所述观点仅代表作者本人观点,不代表AIDD Pro平台,如您发现发布内容...
322 Background: Ramucirumab (RAM), nivolumab (NIVO), and trifluridine/tipiracil (FTD/TPI) were approved for advanced gastric cancer (AGC) between 2010 and 2020 in Japan. However, the impact of these newly approved drugs on survival in the real-world clinical setting is not clear. Methods: ...
Cancer Drugs and Indications Newly Approved By U.S. Food and Drug Administration, May 2005 – April 2007 Anastrozole (Arimidex): Conversion to regular approval for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. Issued September 2005. Bevacizumab (Avas...
Here, we review the existing and emerging interventions for PD with focus on newly approved and investigational drugs for motor symptoms, motor fluctuations, dyskinesia, and balance and gait dysfunction.Similar content being viewed by others Therapeutic Strategies to Treat or Prevent Off Episodes in ...
The development of haematopoiesis involves the coordinated action of numerous genes, some of which are implicated in haematological malignancies. However, the biological function of many genes remains elusive and unknown functional genes are likely to re
Subcutaneous daratumumab (DARZALEX®) co-formulated with recombinant human hyaluronidase (DARZALEX FASPRO®) is approved in several countries, incl
The application of asciminib in newly diagnosed Ph+ CML in chronic phase has been granted priority review by the FDA.1 FDA priority review designation signals drugs that, if approved, would provide significant improvements to safety or efficacy over available treatments. With priority review, the ...
China Background: T790M mutation is well known as the most common mechanism for resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs) for EGFR mutation in non- small-cell lung cancer. Several third-generation EGFR TKIs, such as osimertinib, have been explored and ...
As shown in Table 1, lncRNAs play important roles in the occurrence and development of many tumors, including oral squamous cell carcinoma (OSCC) [14], [15], hepatocellular carcinoma (HCC) [16], [17], [18], colon cancer [19], [20], gastric cancer (GC) [21], [22], [23], ...
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010;54:872–8. Article Google Scholar Knapper S, Russell N, Gilkes A, Hills RK...